Both are copper peptides with similar roles
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Both waste your peptide and compromise your results
Was the cited study performed on BPC-157, TB-500 or the parent molecule
After reconstitution, use solutions promptly under appropriate laboratory conditions and avoid repeated freezethaw cycles
Always consult with a healthcare professional before starting any new treatment regimen, and ensure that you're obtaining these injections from a reputable, licensed source
/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788239.jpeg)
